PER, EPS, PBR and BPS are calculated in-house from the last 4 quarters (2025Q3–2026Q2) · Dividend yield is based on ₩150 per share · Prices as of the 2026-10-02 close
After two consecutive quarters of operating losses in the second half of 2025, Jinyang Pharmaceutical's operating margin recovered to double digits in the first half of 2026, while quarterly net income has shown wide swings tied to non-operating factors.
Revenue rose for four consecutive years from KRW 76.26 billion in 2022 to KRW 120.69 billion in 2025, but operating margin fell sharply from 10.3% in 2024 to 2.1% in 2025.
After operating losses in both the third and fourth quarters of 2025, operating margin recovered to roughly 10% and 13% in the first and second quarters of 2026, respectively.
In the fourth quarter of 2025, despite an operating loss of KRW 2.85 billion, net income attributable to owners surged to KRW 19.33 billion, suggesting a large non-operating impact for the quarter.
At an extraordinary shareholders' meeting in October 2025, the company expanded its board from an owner-centered structure toward professional management and amended its articles to establish a basis for quarterly dividends.
Convertible bond conversions and treasury share disposals (including to Hwanin Pharmaceutical) altered the share count and shareholder composition during 2025.
Jinyang Pharmaceutical was founded in 1971 and listed on KOSDAQ in July 2000 as a pharmaceutical manufacturer. Its core product lines are circulatory system drugs and central nervous system drugs, around which the company's product portfolio is organized.
The company has moved away from a broad, low-volume production strategy toward a concentrated, high-volume model centered on flagship products, a shift widely attributed to regulatory changes such as differentiated GMP evaluation.
Production is centered at its Wonju plant, and the company states it is pursuing new drug and product development along with patent acquisition and technology partnerships for new product launches.
On governance, the company held its first extraordinary shareholders' meeting since listing in October 2025, expanding the board from a three-member, owner-centered structure to a five-member board that includes executives with production and finance backgrounds.
The newly appointed inside directors included a long-serving production executive and an executive who had led the management support division for 21 years, signaling an intent to strengthen professional management.
At the same meeting, the company added a quarterly dividend provision to its articles of incorporation, aiming to diversify shareholder returns for long-term investors.
During 2025, roughly 1.48 million new shares were issued through convertible bond conversions, increasing total shares outstanding, alongside multiple treasury share events including trust contract terminations and disposals to parties such as Hwanin Pharmaceutical and Shinjeongil.
Among listed Korean pharmaceutical companies, it is classified as a mid-sized KOSDAQ pharma player competing with numerous other companies in the circulatory and central nervous system prescription drug markets.
| Quarter | Revenue | Operating profit | Op. margin |
|---|---|---|---|
| 2025Q2 | ₩30.2B | ₩2.5B | 8.2% |
| 2025Q3 | ₩29.2B | -₩900M | −3.2% |
| 2025Q4 | ₩30.3B | -₩2.9B | −9.4% |
| 2026Q1 | ₩32.4B | ₩3.4B | 10.4% |
| 2026Q2 | ₩32.6B | ₩4.2B | 12.9% |
| Year | Revenue | Operating profit | Net income (parent) | Op. margin | ROE | Debt-to-equity |
|---|---|---|---|---|---|---|
| 2022 | ₩76.3B | ₩11.1B | ₩12.3B | 14.6% | 15.9% | 47.5% |
| 2023 | ₩94.1B | ₩9.1B | ₩12.7B | 9.7% | 14.1% | 33.8% |
| 2024 | ₩113.3B | ₩11.7B | ₩29.7B | 10.3% | 24.8% | 89.8% |
| 2025 | ₩120.7B | ₩2.5B | ₩22.3B | 2.1% | 13.9% | 67.5% |
Consolidated basis (financial statements including subsidiaries) · Final figures from DART filings · Net income attributable to owners of the parent · Data as of 2026-08-23
Annual revenue rose for four straight years: KRW 76.26 billion in 2022, KRW 94.11 billion in 2023, KRW 113.33 billion in 2024, and KRW 120.69 billion in 2025.
Operating profit, however, held at double-digit margins in earlier years—KRW 11.14 billion (14.6% margin) in 2022, KRW 9.09 billion (9.7%) in 2023, KRW 11.71 billion (10.3%) in 2024—before falling sharply to KRW 2.53 billion (2.1%) in 2025.
Net income attributable to owners rose from KRW 12.31 billion in 2022 to KRW 12.66 billion in 2023 and KRW 29.69 billion in 2024, then eased to KRW 22.29 billion in 2025; the fact that 2024 net income far exceeded operating profit suggests a meaningful non-operating contribution that year.
On a quarterly basis, operating profit fell from KRW 2.48 billion in the second quarter of 2025 to a loss of KRW 0.94 billion in the third quarter and a deeper loss of KRW 2.85 billion in the fourth quarter, marking two consecutive quarters of operating losses.
Yet owners' net income for the fourth quarter surged to KRW 19.33 billion, a result interpreted as reflecting a large non-operating item unrelated to core operating performance.
Industry ranking data likewise placed Jinyang seventh among KOSDAQ-listed pharma and bio companies by fourth-quarter 2025 owners' net income (KRW 19.3 billion), with a quarter-on-quarter increase described as Alteogen (+KRW 46.9 billion), Dongkoo Bio & Pharma (+KRW 42.9 billion), and Jinyang Pharmaceutical (+KRW 20.3 billion) ranking among the largest gains.
The same analysis noted that Dongkoo Bio & Pharma, Jinyang Pharmaceutical, Estipharm and other companies focused on overcoming base effects and diversifying revenue ranked highly, though the specific composition of the non-operating item was not clearly identified in available disclosures.
Into 2026, operating margin returned to double digits, with first-quarter revenue of KRW 32.40 billion and operating profit of KRW 3.37 billion (about 10.4% margin), and second-quarter revenue of KRW 32.65 billion and operating profit of KRW 4.22 billion (about 12.9% margin); owners' net income was a comparatively stable KRW 2.27 billion and KRW 2.20 billion in those respective quarters.
On a non-consolidated basis, the 2025 net margin stood at 18.47%, placing the company among the group of listed pharmaceutical firms with double-digit net margins.
According to an aggregated analysis of 65 listed Korean pharmaceutical companies' 2025 results, total revenue rose 7.60% year over year to KRW 28.11 trillion, operating profit rose 7.91% to KRW 1.92 trillion, and net income surged 43.25% to KRW 1.54 trillion.
Within this group, the 30 KOSDAQ-listed companies posted revenue of KRW 7.44 trillion (+9.84%), operating profit of KRW 889.8 billion (+22.57%), and net income of KRW 780.0 billion (+36.72%), showing that profit growth among smaller KOSDAQ pharma names outpaced that of larger KOSPI peers.
In net margin comparisons, Jinyang Pharmaceutical recorded 18.47%, ranking behind Samsung Pharm (25.06%), Dongkoo Bio & Pharma (20.67%), and JW Shinyak (19.32%), placing it among the 15 companies with double-digit net margins.
This ranking, however, is based on non-consolidated financial statements and reflects net margin rather than operating margin, warranting caution in interpretation.
Korea's prescription drug market is generally viewed as being in a structural growth phase for circulatory and central nervous system therapeutics, driven by an aging population and rising chronic disease prevalence.
At the same time, government drug pricing controls and intensifying generic competition are common pressures across the industry.
As a mid-to-small-sized player with comparatively limited R&D and capital resources relative to large pharmaceutical companies, Jinyang has pursued a strategy of securing cost competitiveness through concentrated, high-volume production of flagship products.
In October 2025, the company added a quarterly dividend provision to its articles of incorporation through an extraordinary shareholders' meeting, signaling a shift in shareholder return policy away from a once-a-year, year-end dividend structure toward more frequent payouts.
With the board expanded to include new production and finance executives, how improvements in production efficiency and internal management systems feed through to results will be worth watching.
The return to double-digit operating margins in both quarters of the first half of 2026 suggests an effort to move past the weak second half of 2025, but whether this trend continues into the second half will need confirmation from upcoming quarterly results.
The company states it continues to prepare new drug and product development, along with patent acquisition and technology partnerships for new product launches, though specific pipeline timelines or expected revenue contributions are not detailed in available disclosures.
The 2025 treasury share disposals to Hwanin Pharmaceutical and Shinjeongil altered the shareholder base, and whether these relationships expand into broader business cooperation is worth monitoring going forward.
Continued convertible bond conversions could further increase shares outstanding, making per-share dilution effects another point to track.
The current share price trades below per-share net asset value, placing it in a discount range relative to book value.
The price-to-earnings ratio sits toward the lower end of the band in which Jinyang Pharmaceutical has historically traded, a level partly attributable to the fourth-quarter 2025 non-operating net income surge that lifted the trailing four-quarter earnings base.
Dividends have remained at a stable amount centered on year-end payouts in recent years, and the October 2025 amendment establishing a quarterly dividend framework represents a diversification of the shareholder return approach.
Operating profit itself shifted from losses in the second half of 2025 to double-digit margins in the first half of 2026, and whether this recovery continues into subsequent quarters remains to be confirmed.
Given the company's relatively small market capitalization, changes in shares outstanding from convertible bond conversions and treasury share disposals are also a factor worth considering when interpreting these metrics.
PER, EPS, PBR and BPS are all calculated in-house (the same method as Naver and Toss) · Dividend yield = cash dividend per share from DART filings (supplemented by KRX) ÷ current price · As of 2026-08-23
After operating losses in both the third and fourth quarters of 2025, operating margin recovered to about 10.4% in the first quarter of 2026 and about 12.9% in the second quarter. Revenue also continued growing, surpassing KRW 32 billion in both quarters. Whether this trend persists into the second half is a key variable for future results.
At an extraordinary shareholders' meeting in October 2025, the board expanded from three owner-centered directors to five members including executives with production and finance backgrounds.
The same meeting introduced a quarterly dividend provision into the articles of incorporation, aiming to shift dividend policy toward long-term investors. This push toward professional management has the potential to translate into improved internal management systems.
Revenue grew for four consecutive years from 2022 through 2025, reaching close to KRW 120 billion. On a non-consolidated basis, the 2025 net margin of 18.47% placed the company among the group of listed pharmaceutical firms with double-digit net margins.
This figure reflects net margin rather than operating margin, however, and should be considered alongside the impact of non-operating items.
The company posted an operating loss of KRW 0.94 billion in the third quarter of 2025 and KRW 2.85 billion in the fourth quarter, marking two consecutive quarters of losses.
As a result, the full-year operating margin fell sharply from 10.3% in 2024 to 2.1% in 2025, indicating a notable deterioration in core business profitability during the year.
In the fourth quarter of 2025, despite an operating loss, owners' net income surged to KRW 19.33 billion, a result attributed to a large non-operating item.
A similar pattern occurred in 2024, when net income far exceeded operating profit, indicating recurring periods where net income cannot be explained by core operations alone. The nature and recurrence of these non-operating factors are not clearly specified in publicly available disclosures.
During 2025, roughly 1.48 million new shares were issued through convertible bond conversions, increasing total shares outstanding. The same year saw treasury share trust contract terminations and disposals to parties including Hwanin Pharmaceutical and Shinjeongil. The frequency of these share-related events adds volatility to the free float and shareholder composition.
Korea's prescription drug market is subject to government drug pricing controls. Intensifying generic competition and pricing pressure are factors affecting the industry broadly.
Given its revenue concentration in circulatory and central nervous system products, Jinyang Pharmaceutical is also exposed to these policy shifts.
Across five quarters from the second quarter of 2025 through the second quarter of 2026, operating profit alternated between profit, loss, loss, profit, and profit. Net income also showed patterns that are difficult to predict, such as the non-operating surge in the fourth quarter. This volatility adds uncertainty to forward earnings expectations.
As the company transitions from owner-centered management toward professional management, board composition and share-related policies are evolving.
The disposal of treasury shares to specific parties, including Hwanin Pharmaceutical and Shinjeongil, is an event that could influence future governance or business relationships. The direction of these changes has not yet been fully established.
Based on the prior-year pattern (the 2025 third-quarter report was filed on November 14, 2025), this is when the 2026 third-quarter report is expected, providing a check on whether the operating margin recovery seen in the first half of 2026 continued into the third quarter.
Watch for whether the quarterly dividend framework introduced via the October 2025 bylaw amendment is actually implemented, including any board resolution or disclosure related to a first quarterly dividend.
Monitor disclosures for any further changes in shareholding or signs of expanded business cooperation related to the treasury shares disposed of to Hwanin Pharmaceutical and Shinjeongil.
The 2026 annual business report is expected to be filed, allowing final confirmation of whether the 2026 full-year results and operating margin recovery held up on an annual basis.
Jinyang Pharmaceutical saw steady revenue growth from 2022 through 2025, while operating margin swung sharply, falling from 10.3% in 2024 to 2.1% in 2025, reflecting pronounced year-to-year and quarter-to-quarter variability.
The recovery to double-digit operating margins in the first half of 2026 after two consecutive operating losses in the second half of 2025 is a positive signal, but the sharp rise in fourth-quarter net income despite an operating loss in the same period suggests a substantial non-operating influence that warrants careful interpretation.
The board expansion and introduction of a quarterly dividend framework in October 2025 can be viewed as a starting point for change in governance and shareholder returns.
Ongoing share-related events, including new shares from convertible bond conversions and treasury share disposals to parties such as Hwanin Pharmaceutical, mean that share count and shareholder composition volatility also merit attention.
Industry-wide, KOSDAQ-listed pharmaceutical companies showed more pronounced profit growth than larger KOSPI peers, and Jinyang's net margin ranked among the higher tier.
Upcoming quarterly results, the implementation of the quarterly dividend, and further shifts in ownership structure will likely be the key items to watch going forward.
Report written 2026-09-05 · Data as of 2026-09-04
This content is AI analysis of market data and web search results, provided for information only. It is not a solicitation or recommendation to invest. Investment decisions and their consequences are the investor's own responsibility. Data may be delayed or contain errors.